摘要
目的探讨组蛋白去乙酰化酶6(histone deacetylase 6,HDAC6)在大肠癌组织中的表达,分析其与大肠癌患者临床病理因素及预后的相关性。方法采用免疫组织化学法检测86例大肠癌组织(大肠癌组)及其癌旁正常黏膜组织中(癌旁正常组)HDAC6的表达情况,分析其表达与大肠癌临床病理特征及预后的关系。结果 HDAC6在大肠癌组阳性率(65.1%)高于癌旁正常组(10.5%)(P<0.01);大肠癌组HDAC6蛋白阳性率在患者性别、年龄、浸润深度、肿瘤部位分化程度上差异无统计学意义(P>0.05);有淋巴结转移者HDAC6蛋白阳性率(75.5%)高于无淋巴结转移者(48.5%)(P<0.05),且随TNM分期增加HDAC6阳性率增高,差异有统计学意义(P<0.05);大肠癌组HDAC6蛋白阳性与阴性者3a生存率(89.3%与86.7%)比较差异无统计学意义(P>0.05),但HDAC6蛋白阳性者5a生存率(12.5%)低于阴性者(30.0%)(P<0.05)。结论 HDAC6异常表达可能与大肠癌发生、发展有关,HDAC6可作为诊断大肠癌及评估预后的指标之一。
Objective To detect the expression of histone deacetylase 6 （HDAC6） in colorectal cancer and explore its relationship with clinicopathological features and prognosis. Methods Immunohistochemistry was adopted to detect the expression of HDAC6 in colorectal cancer tissue and adjacent normal tissue from 86 patients with colorectal cancer to analyze its correlation with clinicopathological features and prognosis. Results The positive rate of HDAC6 was significantly higher in colorectal cancer tissue （65. 1%） than that in adjacent normal tissue （10.5%） （P〈0.01）, and showed no significant differences in the gender, age, infiltrating depth and differentiation degree （P〉0.05）. The positive rate of HDAC6 was significantly higher in colorectal cancer with lymph node metastasis （75. 5%） than that without lymph node metastasis （48. 5%） （P〈0.05）, and increased significantly with the increased TNM stage （P〈0.05）. There was no significant difference in the 3-year survival rate between positive and negative HDAC6 colorectal cancer tissue （89.3% vs 86.7%） （P〉0.05）, and the 5-year survival rate was significantly lower in positive HDAC6 cancer tissue （12.5 %） than that in negative HDAC6 cancer tissue （30.0 % ） （P〈0.05）. Conclusion The abnormal expression of HDAC6 may be associated with the occurrence and development of colorectal cancer. HDAC6 can be used as a molecular marker for the diagnosis and prognosis prediction of colorectal cancer.
出处
《中华实用诊断与治疗杂志》
2016年第11期1089-1091,共3页
Journal of Chinese Practical Diagnosis and Therapy
